The Art and Science of addressing persistent activity in the wet AMD patient

Management of AMD patients often means more than addressing only the newly formed pathologic vessels.

When addressing suboptimal response in the wet AMD patient, it's the experience with diagnostic imaging that can make a difference.

Involution of mature vessels is a science
as well as an art.

Find out more about Visudyne®. Click here to download more information.

Indications and Usage

Visudyne® is indicated for the treatment of predominantly classic subfoveal choroidal neovascularization due to age-related macular degeneration, pathologic myopia, or presumed ocular histoplasmosis.

Important Safety Information

Visudyne® is contraindicated for patients with porphyria or known hypersensitivity to any component of Visudyne®.

Infusion-related transient back pain occurred with Visudyne® only. Verteporfin infusion induces temporary photosensitivity; patients should avoid exposure of skin and eyes to direct sunlight or bright indoor light for 5 days. To prevent extravasation, avoid fragile hand veins in favor of larger antecubital veins.

Severe vision decrease (≥4 lines) was reported within 7 days in 1% to 5% of patients. Partial recovery occurs in some patients. Do not re-treat these patients until vision completely recovers to pretreatment levels and potential benefits and risks of subsequent treatment are carefully weighed.

The most frequently reported adverse events (10% to 30% incidence) were injection site reactions (including extravasation and rashes), blurred vision, decreased visual acuity, and visual field defects.